AstraZeneca has posted a stronger-than-anticipated profit for the latest quarter and reaffirmed its revenue forecast for 2026, fueled by robust demand for its oncology portfolio. The Anglo-Swedish pharmaceutical giant reported a core operating profit of $5.4 billion for the third quarter, surpassing analyst estimates of $5.1 billion. Revenue rose 15% to $12.8 billion, driven by blockbuster cancer treatments such as Tagrisso and Imfinzi.
Strong Performance in Oncology
The company's oncology division continues to be the primary growth engine, with Tagrisso sales increasing 12% to $1.6 billion and Imfinzi revenue climbing 18% to $1.2 billion. AstraZeneca also highlighted strong uptake of its newer cancer drugs, including Enhertu and Calquence, which contributed to the overall performance. The company's pipeline remains robust, with several late-stage trials expected to yield results in the coming months.
2026 Outlook Reaffirmed
AstraZeneca maintained its guidance for 2026, targeting total revenue of $45 billion to $50 billion. The company expects continued growth from its core therapeutic areas, particularly oncology, respiratory, and cardiovascular diseases. CEO Pascal Soriot expressed confidence in the company's long-term strategy, citing a strong pipeline and expanding global footprint.
Analyst Reactions
Analysts welcomed the results, noting that AstraZeneca's focus on innovation and strategic acquisitions has paid off. The company's recent acquisition of Alexion Pharmaceuticals has bolstered its rare disease portfolio, while partnerships in antibody-drug conjugates have strengthened its oncology offerings. However, some analysts cautioned about potential headwinds from generic competition and pricing pressures in certain markets.
Regional Performance
Regionally, the United States remained the largest market, contributing $5.6 billion in revenue, up 14%. Emerging markets, particularly China, showed strong growth, with revenue increasing 20% to $2.8 billion. The company continues to navigate regulatory challenges in China, but remains optimistic about long-term opportunities.
Future Prospects
Looking ahead, AstraZeneca plans to launch several new products over the next two years, including treatments for non-small cell lung cancer and chronic kidney disease. The company is also investing in next-generation technologies such as cell therapy and gene editing. With a solid financial foundation and a promising pipeline, AstraZeneca is well-positioned to sustain its growth trajectory.
